

What ACA's Uncertain Future Means for Biologics Patents

PUBLICATIONS | LESS THAN 1 MIN READ


February 27, 2020

By: Ted Mathias and Rebecca Clegg
Law360


Axinn partner Ted Mathias and associate Rebecca Clegg authored the *Law360* article, "What ACA's Uncertain Future Means for Biologics Patents."

Click [here](#) to access the article. A subscription is required.

Related People



Ted Mathias



Rebecca L. Clegg

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
AXINN VIEWPOINTS LITIGATION & TRIALS

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved